Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma

Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma

Most patients with head and neck squamous cell carcinomas (HNSCC) are diagnosed at a locally advanced stage and show heterogeneous treatment responses. Low <i>SLC3A2</i> (solute carrier family 3 member 2) mRNA and protein (CD98hc) expression levels are associated with higher locoregional...

Full description

Bibliographic Details
Main Authors: Ayşe Sedef Köseer, Liliana R. Loureiro, Justyna Jureczek, Nicola Mitwasi, Karla Elizabeth González Soto, Julia Aepler, Tabea Bartsch, Anja Feldmann, Leoni A. Kunz-Schughart, Annett Linge, Mechthild Krause, Michael Bachmann, Claudia Arndt, Anna Dubrovska
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
HNSCC
radiotherapy
immunotherapy
CD98hc
SLC3A2
chimeric antigen receptor
Online Access:https://www.mdpi.com/2072-6694/14/7/1677

Internet

https://www.mdpi.com/2072-6694/14/7/1677

Similar Items